Pathogen-specific aAPC
未知生产厂商
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins, modify artificial antigen presenting cells (aAPC), and activate T-cells. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins, modify artificial antigen presenting cells (aAPC), and activate T-cells. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
